Comparison between the Framingham and Prospective Cardiovascular of Münster scores for risk assessment of coronary heart disease in human immunodeficiency virus-positive patients in Pernambuco, Brazil

Metabolic Syndrome and Related Disorders

Volumn 8, Issue 6, 2010, Pages 489-497

  Barros, Zoraya Medeiros ^a   De Alencar Ximenes, Ricardo Arraes ^a,b   Miranda Filho, Demócrito Barros ^a   De Albuquerque, Maria De Fátima Pessoa Militão ^b,c   Melo, Heloísa Ramos Lacerda ^a,b   Carvalho, Érico Higino ^d   Gelenske, Thais ^d   Diniz, George ^c   Bandeira, Francisco ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d Instituto de Medicina Integral Prof Fernando Figueira IMIP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; BRAZIL; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; FEMALE; FRAMINGHAM AND PROSPECTIVE CARDIOVASCULAR OF MUNSTER SCORE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEX; SMOKING;

ADULT; ALGORITHMS; BRAZIL; CARDIOVASCULAR PHYSIOLOGICAL PROCESSES; COHORT STUDIES; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 78649971649     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2009.0100     Document Type: Article

References (46)

1. Henry K, Melroc H., Hucbsch J., Hermundson J, Levine C, Swensen L, Daley J. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328.
2. Savès M, Genevièeve C, Ducimetière P, Leport C, Gwenaël Le Moal G, Philippe Amouyel P, Dominique Arveiler D, Ruida-vets J-B, Reynes J, Bingham A, and Raffi F, for the French WHO MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003;37:292-298.
3. The Data Collection On Adverse Events Of Anti-HIV Drugs (Dad) Study Group. Combination Antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349: 1993-1903.
4. Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, Furrer H, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher1 HC, and the Swiss HIV Cohort Study. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: The Swiss HIV Cohort Study. HIV Med 2006;7:404-410.
5. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperli-pidaemia, and diabetes mellitus: A cohort study. Lancet 1999;353:2093-2099.
6. Klein D, Hurley LB, Quesenberry CP, Sidney S. Do Protease Inhibitors Increase the Risk for Coronary Heart Disease in Patients with HIV-1 Infection?. J AIDS 2002;30:471-477.
7. Holmberg SD, Moorman AC, Williamson JM, Tong T, Ward D, Wood K, Greenberg A, Janssen R. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747-1748.
8. Hadigan C, Meigs JB, Wilson PWF, D'Agostino RB, Davis B, Basgoz N, Sax PE, Grinspoon S. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003;36:909-916.
9. Bergersen BM., Sandvik L., Bruun JN. Elevated Framingham risk score in HIV-positive patients on highly active anti-retroviral therapy: Results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004;8:625-630.
10. Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, Thievaut R, Morfeldt L, De Wit S, Pradier C, Calvo, G, Kirk O, Sabin CA, Phillips AN, Lundgren JD fort he D:A:D Group. The use of the Fra-mingham equation to predict myocardial infarctions in HIV-infected patients: Comparison with Observed events in the D:A:D Study. N Engl J Med 2006;7:218-230.
11. Triant VA, Hang L, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rate and cardiovascular risk factor among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92:2506-2512.
12. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola, D, and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-2486.
13. Matetzky S, Domingo M, Kar S, Noc M, Shah PK, Kaul S, Daar E, Cercek B. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 2003;163:457-460.
14. Boccara F, Ederhy S, Janower S, Benyounes N, Odi G, Cohen A. Clinical characteristics and mid-term prognosis of acute coronary syndrome in HIV-infected patients on anti-retroviral therapy. HIV Med 2005;6:240-244.
15. Hsue PY, Giri K, Erickson S, MacGregor JS, Younes N, Shergill A, Waters DD. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 2004;109:316-319.
16. Jericó C, Knobel H, Montero M, Ordoñez-Llanos J, Ana Guelar A, Gimeno JL, Pere Saballs P, López-Colomés JL, Pedro-Botet J. Metabolic syndrome among HIV-infected patients. Prevalence, characteristic, and related factors. Diabetes Care 2005;28:144-149.
17. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach S, Wanke C. Incidence of metabolic syndrome in cohort of HIV-infected adult and prevalence relative to the US population (National Health and Nutrition Examination Survey). J AIDS 2006;43:458-466.
18. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using international foundation and Adult Treatment Panel III Criteria. Diabetes Care 2007;30:113-119.
19. Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, Cordier L, Pusterla L, Bombelli M, Sega R, Quirino T, Mancia G. HIV and metabolic syndrome: A comparison with the general population. J AIDS 2007;5:426-431.
20. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Michael Nissén M, Taskinen M-R, Leif Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
21. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kum-pusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-age men. JAMA 2002;288:2709-2712.
22. Mondy K, Overton TE, Grubb J, Tong S, Seyfried W, Pow-derly W, Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007;44:726-734.
23. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S, on behalf of the INITIO Trial International Coordinating Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007;21:2445-2453.
24. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Sil-bershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
25. Dube MP, Stein JH, Aberg JA, Torriani FJ, Hodis HN, Schouten J, Levin J, Myers G, Zackin R, Nevin T, Currier JS, for the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency v́irus and receiving anti-retroviral therapy: Recommendations of The Adults AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2003;31:1216-1224.
26. Volberding PA, Murphy RL, Barbaro G, Barbarini G, Bruno R, Cirelli A, Currie PF, Di Lorenzo G, Fantoni M, Filice G, Galli M, Grisorio B, Moroni M, Recusani F, Sacchi P, Scevola D, Stein JH, Torre D, Vittecoq D The Pavia Consensus Statement. AIDS 2003;17 (Suppl 1):S170-S179.
27. Vittecoq D, Escaut L, Chironi G, Teicher E, Monsuez JJ, Andrejak M, Simon A. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 2003;17:S70-S76.
28. De Socio GVL, Parruti G, Quirino T, Ricci E, Schillaci G, Adriani B, Marconi P, Franzetti M, Martinelli C, Vichi F. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study. J Infect 2008; 57:33-40.
29. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith, Jr SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752. (Pubitemid 41532612)
30. Knobel H, Jericó C, Montero M, Sorli ML, Velat M, Guelar A, Saballs P, Pedro-Botet J. Global cardiovascular risk in patients with HIV infection: Concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care and STDs 2007;21:452-457.
31. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10 years follow-up of the Prospective Cardiovascular Münster (PROCAM) study. Circulation 2002;105:310-315.
32. Rose G, McCartney P, Reid DD. Self-administration of a questionnaire on chest pain and intermittent claudication. Br J Prev Soc Med 1977;31:42-48.
33. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005;28:S37-S42.
34. Kozakova M, Palombo C, Paterni M, Anderwald CH, Konrad T, Colgan MP, Flyvbjerg A, Dekker J. Relationship between insulin sensitivity cardiovascular risk investigators. Body composition and common carotid artery remodeling in a healthy population. J Clin Endocrinol Metab 2008;9:3325-3332.
35. Friedewald WT, Levy R, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
36. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of Third Report of The National Education Program (NCEP) expert panel on detection, evaluation, and treatment on high blood cholesterol in adults (ATP III). JAMA 2001;285:2486-2497.
37. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotonsh C, Cifkovae R, Dallongevillee J, Ebrahime S, Faergemanc O, Grahame I, Manciae G, Manger Cats V, Orth-Gomérg K, Pyöräläe K, Rodicio JL, Sanse S, Sansoye V, Sechteme U, Silbere S, Thomsene T, David Woode D. European Society of Cardiology. American Heart Association. American College of Cardiology. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and the other Societies on Cardiovascular Disease Prevention in Clinical Practice. Atherosclerosis 2004;173:381-391.
38. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome. A new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469-480.
39. James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res 2001;9:228S-233S.
40. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174
41. Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, Mack WJ, Cohen MH, Jacobson L, Gange SJ. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007;45:1074-1081.
42. Fox CS, Massaro JM, Hoffmann UP, Pou KM, Maurovich-Horvat P, Liu C-Y, Vasan RS, Murabito JM, Meigs JB, Cupples LA, Ralph B. D'Agostino RB Sr, O'Donnell CJ. Abdominal visceral and subcutaneous adipose tissue compartments. Association with metabolic risk factors in the Framingham Heart Study. Circulation 2007;116:39-48. (Pubitemid 47016245)
43. Mosca L, Edelman D, Mochari H, Christian AH, Paultre F, Pollin I. Waist circumference predicts cardiometabolic and global Framingham risk among women screened during National Woman's Heart Day. J Womens Health (Larchmt) 2006;15:24-34.
44. Tonstad S, Sandvik E, Larsen PG, Thelle D. Gender difference in the prevalence and determinants of the metabolic in screened subjects at risk for coronary heart disease. Metab Syndr Relat Disord 2007;5:174-182 (Abstract).
45. Tonstad S, Hjermann I. A high-risk score for coronary heart disease is associated with the metabolic syndrome in 40-year-old men and women. J Cardiovasc Risk 2003;10:129-135.
46. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PWF, D'Agos-tino RB, Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factor in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;8:130-139.